1.
|
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Completed
Age: No age specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: D791AL00002, V-15-33, OZV1533, NCT00252759
|
|
2.
|
Phase: Phase IV
Type: Treatment
Status: Completed
Age: 19 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: D7913L00067, NCT00608868
|
|
3.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Completed
Age: 18 to5
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1839IL/0143, NCT00234429
|
|
4.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ZENECA-1839IL/0014, NCT00006048
|
|
5.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ZENECA-1839IL/0017, MSKCC-00100, NCT00006049
|
|
6.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: Not specified
Sponsor: NCI
Protocol IDs: SWOG-S0023, CAN-NCIC-BR15, NCCTG-S0023, S0023, NCT00020709, BR15
|
|
7.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CAN-NCIC-BR19, ECOG-CAN-NCIC-BR19, SWOG-CAN-NCIC-BR19, NCIC-BR.19, NCT00049543, BR19
|
|
8.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: TLK286.3020, NCT00080340
|
|
9.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E1302, E1302, NCT00088907
|
|
10.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-08021, ILCP-01/03, EUDRACT-2004-001331-36, NCT00091156
|
|
11.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: SCRI UNKPRI 12, IRUSIRES0215, CPTAIV-0020-417, B9E-US-X423, NCT00193596
|
|
12.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1839IL/0126, NCT00234468
|
|
13.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D791AL00001, V-15-32, NCT00252707
|
|
14.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: D791AC00007, Iressa Pan Asian Study (IPASS), NCT00322452
|
|
15.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: CAN-NCIC-BL11, NCT00352079, BL11
|
|
16.
|
Phase: Phase III
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCCTG-N05C4, N05C4, NCCTG N05C4, NCT00362986
|
|
17.
|
Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 75
Sponsor: Other
Protocol IDs: NCCCTS-05-126, D7913L00054, NCT00455936
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1839IL/0704, EudraCT no.2004-002662-38, NCT00206219
|
|
19.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UCCRC-11089, NCI-3857, NCT00026299, 3857
|
|
20.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Adult
Sponsor: NCI
Protocol IDs: RTOG-0211, RTOG-BR-0211, NCT00052208
|
|
21.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 19 and over
Sponsor: NCI
Protocol IDs: UAB-0162, UAB-F020730006, ZENECA-ZD1839US-0207, AVENTIS-GIA-12139, NCT00062270
|
|
22.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: NCI
Protocol IDs: MSKCC-04010, NCT00085566
|
|
23.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: RPCI-I-17403, ZENECA-IRUSIRES0414, NCT00087334
|
|
24.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: Over 18
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: RPCI-I-04603, ZENECA-IRUSIRES0303, NCT00093652
|
|
25.
|
Phase: Phase II, Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-04033, NCT00096486
|
